Akèy › Myozit › North Carolina
Etid klinik pou Myozit nan North Carolina
12 etid pou Myozit ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
Tèks ofisyèl etid la (Anglè)
Environmental Risk Factors for the Anti-synthetase Syndrome
- NIEHS Clinical Research Unit (CRU), Research Triangle Park
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT01276470Adult and Juvenile Myositis
- NIEHS Clinical Research Unit (CRU), Research Triangle Park
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 100 · Tout sèks · Mizajou Sep 24, 2026 · NCT00017914RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of North Carolina at Chapel Hill - Accepting Adult Patients, Chapel Hill
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients, Durham
Ap rekriteFaz 2/3
Laj 6 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT06154252A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Research Site, Chapel Hill
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Sep 15, 2026 · NCT06916806A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Atrium Health Rheumatology-Southpark, Charlotte
- Duke University Medical Center, Durham
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- University of North Carolina TraCS Institute - CTRC, Chapel Hill
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Aug 28, 2026 · NCT06925542Descartes-08 in Autoantibody Myositis
- University of North Carolina, Chapel Hill
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT07391605A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Charlotte
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Aug 7, 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Statesville, Statesville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chapel Hill
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Jul 28, 2026 · NCT07295847A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Duke University, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT07115745A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Duke University Health System, Durham
Ap rekriteFaz 1
Laj 12 a 70 · Tout sèks · Mizajou May 22, 2026 · NCT06308978Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.